Quantum BioPharma is trading at $3.60 (+11.46%) today, following the release of robust Q2 2026 financial results and the recent FDA clearance for Lucid-MS to enter Phase 2 testing. * The company reported combined cash, equivalents, and digital assets of approximately US$9.5 million as of June 30, 2026. * Operating expenses saw a significant 53% year-over-year reduction in Q2. * Management confirmed that current liquidity supports operations through at least October 2027. * The FDA approved its Investigational New Drug (IND) application for Lucid-MS on August 10, 2026, enabling advancement into a randomized, double-blind, placebo-controlled Phase 2 clinical trial for progressive MS.